TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$50 Million

Affimed NV

At-the-market Offering

Affimed NV is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. It is also developing single and combination therapies to treat cancers and other life-threatening diseases. The company's operations are located in Germany, Europe, and the USA.